•
Sep 30, 2024

Krystal Biotech Q3 2024 Earnings Report

Krystal Biotech's financial performance surged in Q3 2024, driven by strong VYJUVEK sales and strategic advancements.

Key Takeaways

Krystal Biotech reported a net product revenue of $83.8 million for Q3 2024 and $250.1 million since the launch of VYJUVEK in August 2023. The company is progressing with its B-VEC filings in Japan and Europe, with commercial launches expected in 2025. A strong cash position of $694.2 million was maintained at the end of the quarter.

Net product revenue reached $83.8 million in Q3 2024.

JNDA for B-VEC was filed, targeting commercial launches in Japan and Europe in 2025.

French health authority approved early reimbursed access for B-VEC in France.

Cash and investments ended the quarter at $694.2 million.

Total Revenue
$83.8M
Previous year: $8.56M
+879.9%
EPS
$0.91
Previous year: -$0.67
-235.8%
Gross Profit
$77.2M
Previous year: $8.33M
+825.9%
Cash and Equivalents
$374M
Previous year: $373M
+0.2%
Free Cash Flow
$57.8M
Previous year: -$23M
-351.3%
Total Assets
$982M
Previous year: $790M
+24.3%

Krystal Biotech

Krystal Biotech

Forward Guidance

Krystal Biotech anticipates non-GAAP R&D and SG&A expenses to be between $115 million and $125 million for the full year ending December 31, 2024.

Positive Outlook

  • Advancing Jeune Aesthetics’ KB301 to Phase 2 after positive results in Phase 1
  • Expect Committee for Medicinal Products for Human Use (CHMP) opinion on the MAA before year end
  • Anticipates its first European launch in Germany in 1H 2025
  • Registrational IOLITE study is a single arm, open-label study that is expected to commence in 1H 2025.
  • The Company expects to report detailed results of PEARL-1 Cohorts 3 and 4, including redosing, at future scientific conference(s).

Challenges Ahead

  • Uncertainties associated with regulatory review of clinical trials and applications for marketing approvals
  • The availability or commercial potential of VYJUVEK or product candidates
  • Non-GAAP combined R&D and SG&A expense guidance does not include stock-based compensation
  • The Company has not provided a quantitative reconciliation of forecasted non-GAAP combined R&D and SG&A expense to forecasted GAAP combined R&D and SG&A expense because the Company is unable, without making unreasonable efforts, to calculate the reconciling item, stock-based compensation expenses, with confidence
  • This item, which could materially affect the computation of forward-looking GAAP combined R&D and SG&A expense, is inherently uncertain and depends on various factors, some of which are outside of the Company’s control.